Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Short-term Investments: 2023-2025

Historic Short-term Investments for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to $173.7 million.

  • Compass Therapeutics' Short-term Investments rose 76.15% to $173.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $173.7 million, marking a year-over-year increase of 76.15%. This contributed to the annual value of $83.2 million for FY2024, which is 35.09% down from last year.
  • As of Q3 2025, Compass Therapeutics' Short-term Investments stood at $173.7 million, which was up 122.41% from $78.1 million recorded in Q2 2025.
  • In the past 5 years, Compass Therapeutics' Short-term Investments ranged from a high of $173.7 million in Q3 2025 and a low of $71.6 million during Q1 2025.
  • In the last 3 years, Compass Therapeutics' Short-term Investments had a median value of $128.2 million in 2023 and averaged $120.3 million.
  • Examining YoY changes over the last 5 years, Compass Therapeutics' Short-term Investments showed a top increase of 76.15% in 2025 and a maximum decrease of 46.01% in 2025.
  • Compass Therapeutics' Short-term Investments (Quarterly) stood at $128.2 million in 2023, then tumbled by 35.09% to $83.2 million in 2024, then spiked by 76.15% to $173.7 million in 2025.
  • Its Short-term Investments was $173.7 million in Q3 2025, compared to $78.1 million in Q2 2025 and $71.6 million in Q1 2025.